Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 05 04:00PM ET
26.19
Dollar change
-2.21
Percentage change
-7.78
%
Index- P/E- EPS (ttm)-11.56 Insider Own53.42% Shs Outstand6.53M Perf Week-11.82%
Market Cap170.92M Forward P/E- EPS next Y-11.73 Insider Trans0.00% Shs Float3.04M Perf Month-1.02%
Income-75.17M PEG- EPS next Q-2.48 Inst Own33.72% Short Float9.97% Perf Quarter83.79%
Sales0.00M P/S- EPS this Y-12.13% Inst Trans94.12% Short Ratio0.97 Perf Half Y145.39%
Book/sh27.02 P/B0.97 EPS next Y-3.17% ROA-24.53% Short Interest0.30M Perf Year291.48%
Cash/sh18.44 P/C1.42 EPS next 5Y- ROE-36.63% 52W Range6.07 - 92.00 Perf YTD243.70%
Dividend Est.- P/FCF- EPS past 5Y-120.38% ROI-28.92% 52W High-71.53% Beta1.61
Dividend TTM- Quick Ratio12.90 Sales past 5Y-25.00% Gross Margin- 52W Low331.47% ATR (14)3.68
Dividend Ex-Date- Current Ratio12.90 EPS Y/Y TTM61.87% Oper. Margin- RSI (14)43.89 Volatility14.30% 12.96%
Employees49 Debt/Eq0.48 Sales Y/Y TTM- Profit Margin- Recom2.25 Target Price100.33
Option/ShortNo / Yes LT Debt/Eq0.47 EPS Q/Q65.87% Payout- Rel Volume0.45 Prev Close28.40
Sales Surprise-100.00% EPS Surprise-21.00% Sales Q/Q- EarningsNov 13 BMO Avg Volume311.49K Price26.19
SMA20-5.84% SMA50-26.38% SMA20028.59% Trades Volume141,390 Change-7.78%
Date Action Analyst Rating Change Price Target Change
Nov-04-24Initiated JMP Securities Mkt Perform
Apr-12-24Downgrade Jefferies Buy → Hold $5 → $11
Nov-01-22Downgrade Truist Buy → Hold $16 → $6
Nov-01-22Downgrade Cowen Outperform → Market Perform
Aug-13-21Initiated Robert W. Baird Outperform $34
Apr-13-21Initiated Truist Buy $32
Apr-13-21Initiated Morgan Stanley Equal-Weight $24
Apr-13-21Initiated Cowen Outperform
Nov-13-24 07:00AM
Oct-23-24 01:01AM
Sep-27-24 09:43PM
07:03PM
Sep-25-24 04:56AM
04:24AM Loading…
Sep-17-24 04:24AM
Sep-16-24 06:00AM
Sep-14-24 04:56AM
Aug-13-24 10:53PM
05:00PM
Aug-01-24 06:00AM
Jul-12-24 07:41AM
May-10-24 01:54PM
07:00AM
Mar-27-24 12:00PM
10:52PM Loading…
Mar-21-24 10:52PM
05:00PM
Jan-18-24 12:28PM
Jan-16-24 08:00AM
Dec-13-23 10:52AM
10:51AM
Dec-05-23 05:00PM
Nov-13-23 05:00PM
Nov-06-23 07:00AM
Aug-31-23 09:35AM
Aug-14-23 07:00AM
Jun-26-23 04:38PM
May-11-23 07:00AM
Mar-31-23 07:00AM
Mar-22-23 07:57AM
07:04AM Loading…
Feb-17-23 07:04AM
Jan-31-23 05:00PM
Jan-09-23 12:30PM
07:00AM
Dec-13-22 09:35AM
Dec-09-22 09:35AM
Dec-08-22 11:04AM
07:00AM
Nov-14-22 04:07PM
Nov-08-22 07:00AM
Oct-31-22 10:40AM
08:52AM
07:00AM
Oct-18-22 07:00AM
Sep-19-22 07:20AM
Sep-09-22 07:00AM
Sep-06-22 07:00AM
Aug-12-22 07:00AM
Jul-12-22 08:21AM
Jul-11-22 05:28PM
May-27-22 07:00AM
May-18-22 07:00AM
May-16-22 07:00AM
Mar-07-22 07:00AM
Mar-02-22 07:00AM
Nov-15-21 07:00AM
07:00AM
Nov-10-21 11:28AM
Nov-08-21 08:05AM
Sep-16-21 07:00AM
Sep-15-21 04:27PM
Sep-13-21 07:00AM
Sep-02-21 07:00AM
Aug-12-21 07:00AM
Jul-19-21 02:34PM
Jun-21-21 10:06AM
Jun-01-21 07:00AM
May-13-21 07:00AM
Apr-29-21 08:45AM
Apr-27-21 07:00AM
Apr-12-21 07:18AM
Mar-23-21 05:00PM
Mar-19-21 04:25PM
Mar-18-21 08:26PM
Instil Bio, Inc. is a clinical-stage biopharmaceutical company engaged in developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte therapies for the treatment of patients with cancer. The company was founded in August 2018 and is headquartered in Dallas, TX.